Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity

Nicolas Martinez-Calle; Paula Rodriguez-Otero; Sara Villar; Luis Mejías; Ignacio Melero; Felipe Prosper; Patricia Marinello; Bruno Paiva; Miguel Idoate; Jesus San-Miguel

doi:10.3324/haematol.2017.185777

Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity

Haematologica. 2018 Jul;103(7):e318-e321. doi: 10.3324/haematol.2017.185777. Epub 2018 Apr 12.

Authors

Nicolas Martinez-Calle^{1

2

3}, Paula Rodriguez-Otero^{4

2

3}, Sara Villar⁴, Luis Mejías⁵, Ignacio Melero^{3

6}, Felipe Prosper^{4

2

3

7}, Patricia Marinello⁸, Bruno Paiva^{2

3

9}, Miguel Idoate⁵, Jesus San-Miguel^{4

2

3

7}

Affiliations

¹ Hematology Department. Clínica Universidad de Navarra, Spain nmartinezc@unav.es.
² Instituto de Investigación Sanitaria de Navarra (IDISNA), Pamplona Spain.
³ Center for Applied Medical Research (CIMA), University of Navarra, Spain.
⁴ Hematology Department. Clínica Universidad de Navarra, Spain.
⁵ Clinical Department of Pathology, Clínica Universidad de Navarra, Spain.
⁶ Clinical Immunology Department, Clínica Universidad de Navarra, Spain.
⁷ Centro de Investigación Biomédica en Red, Cancer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain.
⁸ Merck Sharp and Dohme Laboratories, New York City, NY, USA.
⁹ CIMALab Diagnostics, University of Navarra, Spain.

No abstract available

Publication types

Case Reports

MeSH terms

Acute Disease
Aged
Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects*
Antineoplastic Agents, Immunological / administration & dosage
Antineoplastic Agents, Immunological / adverse effects*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Autoimmunity
Fatal Outcome
Female
Humans
Lymphocytes, Tumor-Infiltrating / immunology
Lymphocytes, Tumor-Infiltrating / metabolism
Lymphocytes, Tumor-Infiltrating / pathology
Multiple Myeloma / complications
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy
Myocarditis / diagnosis
Myocarditis / etiology*
Myocarditis / metabolism
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
T-Lymphocyte Subsets / immunology
T-Lymphocyte Subsets / metabolism
T-Lymphocyte Subsets / pathology

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
PDCD1 protein, human
Programmed Cell Death 1 Receptor
pembrolizumab